Report Code: A08360 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Dogs have stronger hearing sense compared to humans. They are more sensitive to noise. They suffer from noise aversion, which is sensitivity to loud noises and leads to fear and sometimes anxiety. Sileo has been approved by the FDA to help in the treatment of noise aversion. It is a dexmedetomidine oromucosal gel, and is only available if there is a prescription available by the veterinarian.
Symptoms for noise aversion in dogs include panting, shaking, acting restlessly, trembling, escaping and running all the way, seeking out people, not eating food or refusing to eat, bolting, vomiting or excessive drooling, and defecating or urinating all over the place.
COVID-19 scenario analysis:
Increase in frequency in the adoption rates of pets in developed as well as developing economies, rise in disposable income, and the owners being ready to spend on their pets & animals are the major factors propelling the growth of the pet noise anxiety market. There has also been significant rise in veterinary doctors in both the underdeveloped and developed countries that drive the growth of the pet noise anxiety market. Rise in R&D activities and other advances in therapies and drugs also affect the growth of the pet noise anxiety market positively.
On the other hand, less awareness is observed amongst pet owners in regards to the pet noise anxiety disorders, which is the major challenge faced by the pet noise anxiety market.
On December 4th, 2018, the U.S. Food and Drug Administration approved Pexion tablets commonly known as Imepitoin by the Center for Veterinary Medicine, which help in the treatment of noise aversion in dogs. On June 29th, 2018, FDA issued a second warning for overdosing of Sileo to dogs, owing to the mechanism of the ring-stop, which does not lock the intended dose. During this period, FDA and Zoetis worked together on the instruction manual for the prevention of overdose. During this process, Zoetis worked upon various programs such as training videos, guiding the staff, and the pet owners on handling the product and applying it to the pets. Despite the measures taken, the problem wasn’t solved and the FDA encountered new 34 reports of overdoses in dogs even after the after the June 2018 warning.Â
Veterinary clinics, hospitals, pharmacies, and drug stores are the major consumers of the pet noise anxiety market. Amongst them, veterinary hospitals are the biggest end users in the market. This is due to the rise in prescription of drugs as the adoption rate is going up for pets.
Key benefits of the report:
Questions answered in the pet noise anxiety market research report:
Pet Noise Anxiety Market: Global Opportunity Analysis and Industry Forecast 2020–2027 Report Highlights
Aspects | Details |
---|---|
By Drug Type |
|
By End User |
|
By Medication Type |
|
By Region |
|
Key Market Players | Angelini Pharma Inc, Zoetis, Glaxo Smith Kline, Vets4Pets Limited, Merck & Co., Inc, Pfizer Limited, Adaptil, Physicians Total Care, Inc., Pegasus Laboratories, Inc. |
Loading Table Of Content...
Start reading.
This Report and over 71,229+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers